Updating results

2669 results

Sort: Relevance | Date

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic pain: oral ketamine (ESUOM27)

Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

Evidence summary Published February 2014 Last updated June 2014

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

Evidence summary Published February 2013

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

Summary of the evidence on docetaxel for treating hormone-sensitive metastatic prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2016

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Infantile haemangioma: topical timolol (ESUOM47)

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Digital ulcers: sildenafil (ESUOM42)

Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

Evidence summary Published March 2015

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

Evidence summary Published January 2013

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

Summary of the evidence on tranexamic acid for significant haemorrhage (bleeding) after trauma (major injury) to inform local NHS planning and decision-making

Evidence summary Published October 2012

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

Summary of the evidence on aclidinium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

Evidence summary Published May 2016

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

Summary of the evidence on the sufentanil sublingual tablet system for treating post­operative pain to inform local NHS planning and decision-making

Evidence summary Published March 2016

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making

Evidence summary Published March 2016

Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

Summary of the evidence on perampanel for partial-onset seizures in epilepsy (in people aged 12 and over) to inform local NHS planning and decision-making

Evidence summary Published December 2012

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making

Evidence summary Published December 2015

Biopatch for venous or arterial catheter sites (MIB117)

Advice on the use of Biopatch hydrophilic foam dressing with chlorhexidine gluconate (CHG) for venous or arterial catheter sites to aid local decision-making

Medtech innovation briefing Published August 2017

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..

Evidence summary Published January 2013

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

Evidence summary Published July 2013 Last updated September 2014

Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Hypersalivation: oral glycopyrronium bromide (ESUOM15)

Summary of the evidence on oral glycopyrronium bromide for treating hypersalivation (sialorrhoea) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published June 2013

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

Evidence summary Published December 2015

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015